BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 11, 2004
 |  BioCentury  |  Strategy

Breathing on revenues

Etiologics Ltd. and Argenta Discovery Ltd. say last week's all-stock merger brings together the components of a complete drug discovery engine: Argenta's chemistry and Etiologics' biological focus on respiratory diseases. It also provides a revenue stream from Argenta's contract research work for large pharma that the company can use to get from discovery into the clinic.

Etiologics has a series of models for chronic obstructive pulmonary disease (COPD) and compounds in the research stage, said Stephen Readers, investment manager with MVM, which...

Read the full 404 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >